新兴耐药指数:追踪新抗生素的早期耐药
本文提出新兴耐药指数(ERI),一种整合耐药比例与趋势、监测系统可用性、抗生素批准至耐药检测时间差及耐药菌暴发年均数等参数的定量工具,用于追踪新抗生素的耐药发展。基于27个欧盟国家、4个欧洲自由贸易联盟国家和英国的38个监测系统数据,分析13种新抗生素发现,所有针对革兰阴性菌的新抗生素均出现快速耐药,亚胺培南-瑞来巴坦和头孢地尔ERI值尤其高。
要点
- ERI可定量动态监测新抗生素早期耐药趋势。
- 所有针对革兰阴性菌的新抗生素均出现快速耐药。
- 旧β-内酰胺类联合新抑制剂的组合尤其易快速耐药。
核心结论
- ERI可作为定量动态工具监测耐药趋势,支持及时监测、抗生素政策决策及研发优先级。
研究设计与样本
- 通过文献综述和38个监测系统报告提取13种新抗生素的耐药与抗菌药物消费数据,覆盖27个欧盟国家、4个欧洲自由贸易联盟国家和英国。
主要发现
- 所有针对革兰阴性菌的新抗生素均出现快速耐药发展。
- 亚胺培南-瑞来巴坦和头孢地尔的ERI值尤其高。
- 旧β-内酰胺类联合新抑制剂的组合尤其易快速耐药。
关键数值与推荐
- ERI纳入参数:耐药合并比例与趋势、耐药与抗菌药物消费监测系统可用性、抗生素批准至耐药检测时间差、耐药菌暴发年均数。
临床怎么用
- ERI可用于监测新抗生素耐药趋势,辅助抗生素政策制定和研发优先级排序。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The high clinical burden of antimicrobial resistance (AMR) and the dwindling antibiotic pipeline demand standardised tools to monitor resistance development to new antibiotics. The Emerging Resistance Index (ERI) is a novel quantitative tool designed to track resistance to newly developed antibiotics. The ERI incorporates various parameters: AMR pooled proportions and trends, availability of AMR and antimicrobial consumption surveillance systems, time lag between antibiotic approval and resistance detection, and the average annual number of outbreaks caused by resistant strains. AMR and antimicrobial consumption data on 13 new antibiotics were extracted by reviewing the literature and the reports from 38 surveillance systems included in the European Clinical Research Alliance on Infectious Diseases-The Epidemiology Network central data repository, encompassing 27 EU countries, four European Free Trade Association countries, and the UK. Our analysis revealed rapid resistance development to all new Gram-negative-targeting antibiotics, with particularly high ERI values for imipenem-relebactam and cefiderocol. Combinations of old β-lactams with novel inhibitors were especially prone to rapid resistance development. The ERI could offer a quantitative and dynamic tool for monitoring resistance trends. Also, the ERI could support more timely surveillance efforts, inform antibiotic policy decisions, and aid in prioritising antibiotic research and development.
引用
- Garlasco J, Arieti F, Morra M, et al. The Emerging Resistance Index: tracking early resistance to new antibiotics. Lancet Infect Dis. 2025. PMID: 41067238. doi:10.1016/S1473-3099(25)00501-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。